Inovio Pharmaceuticals Inc  

(Public, NYSEMKT:INO)   Watch this stock  
Find more results for AMEX:INO
2.61
-0.04 (-1.51%)
After Hours: 2.62 +0.01 (0.38%)
Apr 23, 5:04PM EDT  
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 2.52 - 2.65
52 week 0.55 - 3.95
Open 2.64
Vol / Avg. 2.93M/7.79M
Mkt cap 626.78M
P/E     -
Div/yield     -
EPS -0.35
Shares 240.15M
Beta 3.71
Inst. own 9%
May 22, 2014
Inovio Pharmaceuticals Annual Shareholder Meeting - 9:00AM EDT - Add to calendar
Mar 17, 2014
Q4 2013 Inovio Pharmaceuticals Earnings Release
Mar 17, 2014
Q4 2013 Inovio Pharmaceuticals Earnings Conference Call
Mar 3, 2014
Inovio Pharmaceuticals at Cowen Health Care Conference
Feb 11, 2014
Inovio Pharmaceuticals at Biotechnology Industry Organization CEO & Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -889.12% -490.69%
Operating margin -460.08% -145.12%
EBITD margin - -144.39%
Return on average assets -70.38% -99.06%
Return on average equity -108.55% -152.12%
Employees 53 -
CDP Score - -

Address

11494 SORRENTO VALLEY ROAD
SAN DIEGO, CA 92121-1318
United States - Map
+1-858-5976006 (Phone)
+1-267-4404242 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Inovio Pharmaceuticals, Inc. is engaged in the development of a new generation of vaccines, called synthetic vaccines, focused on cancers and infectious diseases. The Company's SynCon technology enables the design of universal vaccines capable of providing cross-protection against existing or changing strains of pathogens, such as influenza and human immunodeficiency virus (HIV). The Company's electroporation delivery technology uses brief, controlled electrical pulses to increase cellular uptake of the vaccine. The Company's clinical programs include cervical dysplasia (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus (HCV) and HIV vaccines. It is advancing preclinical research and clinical development for a universal seasonal/pandemic influenza vaccine, as well as preclinical work for other products, including malaria and prostate cancer vaccines. As of December 31, 2011 it owned 16.1% interest in VGX Int�l.

Officers and directors

J. Joseph Kim Ph.D. President, Chief Executive Officer, Director
Age: 44
Bio & Compensation  - Reuters
Peter D. Kies Chief Financial Officer
Age: 49
Bio & Compensation  - Reuters
Niranjan Y. Sardesai Ph.D. Chief Operating Officer
Age: 45
Bio & Compensation  - Reuters
Mark L. Bagarazzi M.D. Chief Medical Officer
Age: 52
Bio & Compensation  - Reuters
Avtar S. Dhillon M.D. Non-Executive Chairman of the Board
Age: 52
Bio & Compensation  - Reuters
Simon X. Benito Independent Director
Age: 68
Bio & Compensation  - Reuters
Angel Cabrera Ph.D. Independent Director
Age: 45
Bio & Compensation  - Reuters
Morton Collins Ph.D. Independent Director
Age: 77
Bio & Compensation  - Reuters
Adel A. F. Mahmoud M.D., Ph.D. Independent Director
Age: 71
Bio & Compensation  - Reuters